Results 11 to 20 of about 311,527 (352)
Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature [PDF]
Toxins, 2017 Botulinum neurotoxins are diverse proteins. They are currently represented by at least seven serotypes and more than 40 subtypes. New clostridial strains that produce novel neurotoxin variants are being identified with increasing frequency, which ...
Michael W. Peck +24 more
doaj +6 more sources
Current status and future directions of botulinum neurotoxins for targeting pain processing. [PDF]
, 2015 Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into peripheral tissues such as skin, muscles, and joints, alter nociceptive processing otherwise initiated by inflammation or nerve injury in animal models and humans.
Pellett, Sabine +2 more
core +13 more sources
Intestinal Absorption of Botulinum Toxins of Different Molecular Sizes in Rats [PDF]
Infection and Immunity, 1977 Shunji Sugii +2 more
openalex +2 more sources
Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. [PDF]
EMBO Journal, 1986 Ulrich Eisel +8 more
openalex +2 more sources
Headache and botulinum toxin [PDF]
The Journal of Headache and Pain, 2005 The authors discuss clinical and international experience about botulinum toxins (BTX types A and B) in headache treatment. Data from literature suggest good results for the treatment of tension-type headache, migraine and chronic tension-type headache. In the present paper mechanisms of action and injection sites will also be discussed.
Massimo Camerlingo, Mauro Porta
openaire +3 more sources
Botulinum Toxin: An Update on Pharmacology and Newer Products in Development
Toxins, 2021 Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects.
S. Choudhury +3 more
semanticscholar +1 more source
Toxins, 2021 Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide
Alessandro Picelli +6 more
doaj +1 more source
Toxins, 2020 Botulinum toxins (BoNTs) are a true wonder of nature [...]
Siro Luvisetto
doaj +1 more source
rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
Frontiers in Microbiology, 2022 Botulinum neurotoxin (BoNT) is one of the most dangerous bacterial toxins and a potential biological weapon component. BoNT mechanism of pathological action is based on inhibiting the release of neurotransmitters from nerve endings.
Artem A. Derkaev +9 more
doaj +1 more source
Botulinum Toxin in Movement Disorders: An Update
Toxins, 2021 Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological ...
Charenya Anandan, J. Jankovic
semanticscholar +1 more source